Pyr3 - ≥98%, high purity , CAS No.1160514-60-2, Channel blocker of TRPC3

Item Number

P275699

• Synonyms: J-003374 | AKOS024457787 | 1-[4-[(2,3,3-Trichloro-1-oxo-2-propen-1-yl)amino]phenyl]-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid | CS-0028846 | GTPL4293 | ethyl 1-(4-(2,3,3-trichloroacrylamido)phenyl)-5-(trifluoromethyl)-1h-pyrazole-4-carboxylate | 1
• Specifications & Purity: Moligand™, ≥98%
• Biochemical and Physiological Mechanisms: Selective TRPC3 channel blocker (IC 50 = 0.7 μM, Ca 2+ influx). Diminishes depolarization in the immature cortex. Blunts BDNF secretion and shows anti-inflammatory effects. Shows neuroprotective effects in vivo.
• Storage Temp: Store at -20°C,Desiccated
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: CHANNEL BLOCKER
• Mechanism of action: Channel blocker of TRPC3
• Note: Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Product Description

Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.

General description

Pyr3, a pyrazole compound, selectively inhibits the canonical transient receptor potential channel 3 (TRPC3).

TRPC3 is a member of TRPCs which control influxes of Ca2+ and other cations that induce diverse cellular processes upon stimulation of plasma membrane receptors coupled to phospholipase C. TRPC3 has been implicated in diverse biological functions, including B cell receptor-mediated Ca2+ oscillations, T cell receptor-dependent Ca2+ entry pathway, and cardiac hypertrophy. 

In addition, the transverse aortic constriction operation-induced increase in expression of atrial natriuretic peptide mRNA, a reliable marker for cardiac hypertrophy, was also suppressed by Pyr3.